Effects of Ramipril and Telmisartan on Plasma Concentrations of Low Molecular Weight and Protein Thiols and Carotid Intima Media Thickness in Patients with Chronic Kidney Disease

Table 3

Drug effects on LMW thiols.

	Group 1 ()			Group 2 ()
	Baseline	Telmisartan/ramipril; 40/5 mg/day	p value	Baseline	Telmisartan; 80 mg/day	p value
	Mean ± SD; or; median (IQR)	Mean ± SD; or; median (IQR)		Mean ± SD; or; median (IQR)	Mean ± SD; or; median (IQR)
Total LMW thiols
t-CysGly, µmol/L	31.6 ± 8.8	31.1 ± 8.5	0.89	28.8 ± 8.4	25.6 ± 7.9	0.35
t-Hcy, µmol/L	16.3 (12.1–26.3)	17.3 (10.3–27.6)	0.90	19.2 (11.8–23.7)	14.4 (11.2–19.2)	0.27
t-Cys, µmol/L	391 ± 89	404 ± 122	0.77	370 ± 109	341 ± 94	0.49
t-GSH, µmol/L	7.4 ± 2.1	7.7 ± 1.8	0.71	7.6 ± 3.2	7.6 ± 4.6	1.00
t-GluCys, µmol/L	5.7 (4.5–6.0)	5.7 (4.4–9.7)	0.38	5.4 (3.5–7.6)	4.4 (3.2–7.2)	0.95
Sum of total LMW thiols, µmol/L	458 ± 106	472 ± 144	0.79	432 ± 122	400 ± 112	0.51
Reduced LMW thiols
r-CysGly, µmol/L	5.8 ± 1.6	5.5 ± 1.6	0.65	6.6 ± 2.6	6.4 ± 1.7	0.83
r-Hcy, µmol/L	0.20 (0.13–0.37)	0.17 (0.12–0.36)	0.57	0.29 (0.18–0.37)	0.23 (0.17–0.29)	0.42
r-Cys, µmol/L	20.9 ± 4.7	19.7 ± 4.7	0.54	21.9 ± 3.5	21.0 ± 4.4	0.58
r-GSH, µmol/L	1.01 (0.74–1.31)	0.94 (0.47–1.37)	0.91	1.11 (0.85–1.67)	1.10 (0.71–1.60)	0.34
r-GluCys, µmol/L	0.35 (0.22–0.58)	0.41 (0.31–0.47)	0.85	0.37 (0.27–0.44)	0.43 (0.33–0.45)	0.97
Sum of reduced sLMW thiols, µmol/L	28.4 ± 5.9	26.1 ± 5.1	0.32	30.5 ± 6.0	29.3 ± 5.8	0.62
Thiols redox status
LMW redox, %	0.066 ± 0.023	0.061 ± 0.025	0.62	0.078 ± 0.030	0.079 ± 0.028	0.93